Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture
about
Postural changes in blood pressure associated with interactions between candidate genes for chronic respiratory diseases and exposure to particulate matterAngiotensin II in inflammation, immunity and rheumatoid arthritisEffects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction RiskExtracellular matrix molecules: potential targets in pharmacotherapy.Candesartan reduces the innate immune response to lipopolysaccharide in human monocytesCombination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interactionInfiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis.Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytesMatrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemiaClinical trial update: focus on the ONTARGET studyVascular benefits of angiotensin receptor blockers.Angiotensin II is related to the acute aortic dissection complicated with lung injury through mediating the release of MMP9 from macrophages.Results of the ONTARGET and TRANSCEND studies: an update and discussion.Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen.Transcriptional regulation of beta2-microglobulin demonstrated via a novel genomic and proteomic analysis of percutaneously collected peripheral atheroma.Angiotensin II and the vascular phenotype in hypertension.The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.The effect of high glucose on the inhibitory action of C21, a selective AT2R agonist, of LPS-stimulated tissue factor expression in human mononuclear cells.Angiotensin II Differentially Induces Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Production and Disturbs MMP/TIMP BalanceCardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI.Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.Association of angiotensin II type I and type II receptor genes polymorphisms with the presence of premature coronary disease and metabolic syndrome.Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation.Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis.Angiotensin II induces NF-κB, JNK and p38 MAPK activation in monocytic cells and increases matrix metalloproteinase-9 expression in a PKC- andRho kinase-dependent manner.
P2860
Q24657334-FE2C3652-B325-4C60-ADE4-8974EF8F994DQ26991828-390E8308-ABEF-4B61-84B0-8713F7F33BA4Q28076223-EEF76BBF-194F-46AD-902F-E783DBC3D1BDQ33694487-72C2813B-FCB7-4EF4-BD1D-BC4B13A8A2D6Q34087095-DBE52A7E-C90E-4BE3-AC09-0E2965C4772DQ34231611-0E6C2B46-2979-42D6-ADFB-6A1C301DEB78Q35607377-9277503E-6734-4774-A272-F2C862A630E0Q35612987-5C435121-C57C-4C1C-A1C7-C866481FB2BEQ35674048-5989045D-9434-44DE-AC10-951F1E447C89Q36596857-CAFD44D4-B5A4-430E-86B3-A1511D681099Q36861584-26FD0A57-3B92-4298-815D-73970F7637DEQ36878567-B383BE77-0196-44A3-8B36-CDF81AB7D2EBQ37167526-31E00A6C-B195-4BE8-B2D7-9D8E0298B0A3Q37210914-F4CE3520-38B7-49C8-BD9D-D9C237EFE768Q37700335-7500AB04-15E5-4047-8629-B3372DA9881EQ37859447-EED8A354-68DA-45C7-B45D-FC4A350B3363Q38113246-20BD4758-AECB-4CB5-99CE-8743D803371EQ38175345-51EBBAC8-4274-41AC-A88B-A56DC3EF8FC2Q41031121-C9B59F27-9565-49B9-BDA3-E4BE75EA6368Q41814560-35B78B66-167D-4EF9-A1D0-BC72E096AAB5Q41915019-43128AD3-62EB-4B1F-B015-3ED6BA482E0FQ46636762-410B6441-2143-4B88-A852-21676E93C162Q46950810-23F2107A-730B-4723-8543-2A7A925399E0Q47938517-D7DFDC0F-D419-4D0E-9C7A-76453CCB4B1DQ51070174-5ABCEF20-AADC-463E-88D6-A71BEC7D2026Q54390730-AFA64196-2FFF-4DDB-84F2-B75309C28476
P2860
Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Angiotensin II increases human ...... atherosclerotic plaque rupture
@ast
Angiotensin II increases human ...... atherosclerotic plaque rupture
@en
Angiotensin II increases human ...... atherosclerotic plaque rupture
@nl
type
label
Angiotensin II increases human ...... atherosclerotic plaque rupture
@ast
Angiotensin II increases human ...... atherosclerotic plaque rupture
@en
Angiotensin II increases human ...... atherosclerotic plaque rupture
@nl
prefLabel
Angiotensin II increases human ...... atherosclerotic plaque rupture
@ast
Angiotensin II increases human ...... atherosclerotic plaque rupture
@en
Angiotensin II increases human ...... atherosclerotic plaque rupture
@nl
P2093
P3181
P356
P1476
Angiotensin II increases human ...... atherosclerotic plaque rupture
@en
P2093
P304
P3181
P356
10.1189/JLB.1204715
P407
P577
2005-07-01T00:00:00Z